SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CNSI Cambridge Neuroscience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (85)2/10/1997 8:01:00 AM
From: TheSlowLane   of 675
 
Big stroke article in the Boston Globe today...focus on TPA. There is a front page article in the Globe today about TPA (tissue plasminogen activator). Studies presented at the California conference indicate that they are having good results with TPA, excellent results in some cases. Lots of caveats though, and I'd be interested to hear comments on how CERESTAT measures up against TPA. TPA must be administered within three hours of onset of stroke. This is an absolute requirement. Administering outside the 3-hour window can induce brain hemorhage. Also, this treatment is ONLY appropriate for a stroke caused by clot, not by a burst blood vessel, so there are severe limitations on how and when it should be applied. There was an oblique reference to work being done on "neuroprotectants", but the article said that trials of these drugs were producing mixed results. None of the drugs in this class were mentioned by name except for Citicoline. Effectiveness of citicoline is comparable to TPA, "which produced a 30% increase in the proportion of patients with full recovery or only minimal disability. I sent e-mail to the author of the article to find out why Cerestat was (to my perfectly unbiased mind) conspicuously absent from mention. Comments?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News